ClinicalTrials.gg
CompletedNCT04057040Updated Aug 7, 2025

Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

A Phase 2 interventional study of PTG-300 and Placebo in Polycythemia Vera, sponsored by Protagonist Therapeutics, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Protagonist Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.

Enrollment
46th of 150
70 · median 40
Started
2019
with 6 others
Phase 2
68 of 179
7 open now
Registered
145th of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 46th largest by enrollment of the 150 interventional ones that give a count, is one of 7 that started in 2019, is one of 68 in phase 2, and was the 145th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.

Read the detailed description

Phase 2 study in approximately sixty subjects previously diagnosed with Polycythemia Vera who require phlebotomy on a routine basis. There is a 28 week dose finding phase to identify a dose that maintains hematocrit \<45%. Subjects who successfully complete the dose finding phase will be entered into a 12 week randomized withdrawal phase to confirm the response. Subsequently patients will enter into an up to 3 year open label extension to investigate long term safety.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • polycythemia vera
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria: All subjects must meet ALL of the following inclusion criteria to be enrolled.

  1. Male and female subjects aged 18 years or older.
  2. Meet revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia vera.
  3. Records of all phlebotomies performed for at least 28 weeks (preferably up to 52 weeks) before dosing are available.
  4. Subjects who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before screening and have recovered from any adverse events due to cytoreductive therapy.
  5. Subjects receiving cytoreductive therapy with hydroxyurea, interferon, or ruxolitinib must have received cytoreductive therapy for at least 24 weeks and be on a stable dose or have a decreasing dose (Medical Monitor approval required) for at least 8 weeks before dosing and with no planned change in dose.

Main Exclusion Criteria: Subjects must meet NONE of the following exclusion criteria to be enrolled:

  1. Active or chronic bleeding within 4 weeks of screening.
  2. Meets the criteria for post-PCV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
  3. Known primary or secondary immunodeficiency.
  4. Any surgical procedure requiring general anesthesia within 1 month prior to screening or planned elective surgery during the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Dose finding PTG-300 (Part 1); PTG-300 (Part 2); Open label extension PTG-300 (Part 3)

    Drug: PTG-300

  • Experimental
    Dose finding PTG-300 (Part 1); Placebo (Part 2); Open label extension PTG-300 (Part 3)

    Drug: PTG-300 · Drug: Placebo

Interventions

  • Active

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Proportion of responders during the blinded randomized withdrawal period (Week 29 to Week 41).

    A subject will be considered a responder during the blinded randomized withdrawal phase if hematocrit control is maintained without phlebotomy eligibility. "Phlebotomy eligibility" is defined as any one of the following criteria being met: * hematocrit ≥45% that was ≥3% higher than Week 29 pre-randomization hematocrit value, or * hematocrit \>48%, or * an increase of ≥5% in hematocrit compared to Week 29 pre-randomization hematocrit value.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in rate of phlebotomy events between Week 17 through Week 29 (inclusive; 12 weeks) compared to each subject's historical rate.

    Time frame: 12 weeks

  2. Change in rate of phlebotomy events between Week 1 through Week 29 (inclusive; 28 weeks) compared to each subject's historical rate.

    Time frame: 28 weeks

  3. Proportion of subjects achieving a response at Week 29, with response defined as having achieved the absence of "phlebotomy eligibility" during the efficacy evaluation phase beginning at Week 17 and continuing to Week 29.

    "Phlebotomy eligibility" in Part 1 is defined as a hematocrit ≥45% that was ≥3% higher than baseline level (defined as Part 1 pre-dose Day 1) or a hematocrit \>48%.

    Time frame: 12 Weeks

  4. Proportion of subjects with reduction in the rate of phlebotomy events beginning at the Week 17 visit and continuing to Week 29 (12 weeks) compared to each subject's historical rate.

    Time to "phlebotomy eligibility" from Week 29 to Week 41/End of Part 2.

    Time frame: 12 Weeks

07

Study locations

16 sites
  • Mayo Clinic - Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Marin Cancer Care
    Greenbrae, California 94904, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • University of Kansas
    Westwood, Kansas 66205, United States
  • Pontchartrain Cancer Care
    Covington, Louisiana 70433, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Karmanos Cancer Center
    Detroit, Michigan 48201, United States
  • Mount Sinai
    New York, New York 10029, United States
  • New York Presbyterian Hospital - Weill Cornell Medical Center
    New York, New York 10065, United States
  • Cleveland Clinic - Taussig Cancer Center
    Cleveland, Ohio 44106, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Sahyadri Super Specialty Hospital
    Pune, Maharashtra 411004, India
  • All India Institute of Medical Sciences
    Rishikesh, Uttarakhand 249203, India
08

References and documents

Publications

  • Kremyanskaya M, Kuykendall AT, Pemmaraju N, Ritchie EK, Gotlib J, Gerds A, Palmer J, Pettit K, Nath UK, Yacoub A, Molina A, Saks SR, Modi NB, Valone FH, Khanna S, Gupta S, Verstovsek S, Ginzburg YZ, Hoffman R; REVIVE Trial Investigators. Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. N Engl J Med. 2024 Feb 22;390(8):723-735. doi: 10.1056/NEJMoa2308809. PubMed 38381675 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Feb 2023, 40 months.

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 135. This study's 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2019
First posted
Aug 14, 2019
StartActual
Oct 1, 2019
Primary completionActual
Feb 14, 2023
CompletionActual
Jun 17, 2024
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04057040
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2019
Start date
Oct 1, 2019
Primary completion
Feb 14, 2023
Completion
Jun 17, 2024
Last update
Aug 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion